PMID- 25674225
OWN - NLM
STAT- MEDLINE
DCOM- 20151028
LR  - 20181113
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 7
IP  - 12
DP  - 2014
TI  - Clinical significance of chromosome 1p/19q loss of heterozygosity and Sox17 
      expression in oligodendrogliomas.
PG  - 8609-15
AB  - OBJECTIVE: To study chromosome 1p/19q loss of heterozygosity (LOH) and Sox17 
      protein expression in oligodendrogliomas and correlate this loss with 
      clinicopathological features. METHODS: This study included 100 cases of 
      oligodendrogliomas at the First Affiliated Hospital of Xinjiang Medical 
      University from 2003 to 2014. The cases included paraffin-embedded tissues from 
      50 low-grade oligodendrogliomas and 50 anaplastic oligodendrogliomas. Chromosome 
      1p/19q LOH was detected by fluorescence in situ hybridization (FISH) and Sox17 
      protein expression was analyzed by immunohistochemistry. Clinicopathological 
      characteristics of the oligodendrogliomas were compared and prognosis analyzed 
      using Cox regression and Kaplan-Meier analyses. RESULTS: The LOH positivity rate 
      of 1p/19q was 52% in 50 cases of low-grade oligodendrogliomas and 68% in 50 cases 
      of anaplastic oligodendrogliomas (P = 0.102). The rates of Sox17 expression were 
      significantly different in oligodendrogliomas (82%) and anaplastic 
      oligodendrogliomas (62%, P = 0.026). Single factor analysis determined that 
      1p/19q LOH (P = 0.000), Sox17 protein expression (P = 0.000), location (P = 
      0.001), chemotherapy (P = 0.000), and radiation therapy (P = 0.001) were 
      associated with oligodendroglioma patient prognosis. Cox multiple factors 
      regression analysis determined that 1p/19q LOH and Sox17 expression were 
      independent prognostic factors of oligodendrogliomas. CONCLUSION: In this study, 
      oligodendroglioma patients with 1p/19q LOH and Sox17 protein expression had a 
      better prognosis. Thus, analysis of 1p/19q LOH and Sox17 protein expression could 
      significantly enhance diagnostic accuracy, guide treatment, and improve the 
      prognosis.
FAU - Li, Junzhi
AU  - Li J
AD  - Department of Pathology, First Affiliated Hospital of Xinjiang Medical University 
      Xinjiang Uyger Automatic Region, Urumqi 830054, China.
FAU - Miao, Na
AU  - Miao N
AD  - Department of Pathology, First Affiliated Hospital of Xinjiang Medical University 
      Xinjiang Uyger Automatic Region, Urumqi 830054, China.
FAU - Liu, Ming
AU  - Liu M
AD  - Department of Pathology, First Affiliated Hospital of Xinjiang Medical University 
      Xinjiang Uyger Automatic Region, Urumqi 830054, China.
FAU - Cui, Wenli
AU  - Cui W
AD  - Department of Pathology, First Affiliated Hospital of Xinjiang Medical University 
      Xinjiang Uyger Automatic Region, Urumqi 830054, China.
FAU - Liu, Xia
AU  - Liu X
AD  - Department of Pathology, First Affiliated Hospital of Xinjiang Medical University 
      Xinjiang Uyger Automatic Region, Urumqi 830054, China.
FAU - Li, Xinxia
AU  - Li X
AD  - Department of Pathology, First Affiliated Hospital of Xinjiang Medical University 
      Xinjiang Uyger Automatic Region, Urumqi 830054, China.
FAU - Shi, Xiaoli
AU  - Shi X
AD  - Department of Pathology, First Affiliated Hospital of Xinjiang Medical University 
      Xinjiang Uyger Automatic Region, Urumqi 830054, China.
FAU - Qing, Song
AU  - Qing S
AD  - Department of Pathology, First Affiliated Hospital of Xinjiang Medical University 
      Xinjiang Uyger Automatic Region, Urumqi 830054, China.
FAU - Ma, Yuqing
AU  - Ma Y
AD  - Department of Pathology, First Affiliated Hospital of Xinjiang Medical University 
      Xinjiang Uyger Automatic Region, Urumqi 830054, China.
FAU - Zhang, Wei
AU  - Zhang W
AD  - Department of Pathology, First Affiliated Hospital of Xinjiang Medical University 
      Xinjiang Uyger Automatic Region, Urumqi 830054, China.
FAU - Biekemituofu, Hadeti
AU  - Biekemituofu H
AD  - Department of Pathology, First Affiliated Hospital of Xinjiang Medical University 
      Xinjiang Uyger Automatic Region, Urumqi 830054, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141201
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (SOX17 protein, human)
RN  - 0 (SOXF Transcription Factors)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/analysis
MH  - *Brain Neoplasms/genetics/metabolism/mortality
MH  - Child
MH  - *Chromosomes, Human, Pair 1/genetics
MH  - *Chromosomes, Human, Pair 19/genetics
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Loss of Heterozygosity/*genetics
MH  - Male
MH  - Middle Aged
MH  - *Oligodendroglioma/genetics/metabolism/mortality
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - SOXF Transcription Factors/*biosynthesis
MH  - Young Adult
PMC - PMC4313992
OTO - NOTNLM
OT  - 1p/19q LOH
OT  - Oligodendroglioma
OT  - Sox17
OT  - clinical features
OT  - prognosis
EDAT- 2015/02/13 06:00
MHDA- 2015/10/29 06:00
PMCR- 2014/12/01
CRDT- 2015/02/13 06:00
PHST- 2014/10/21 00:00 [received]
PHST- 2014/12/01 00:00 [accepted]
PHST- 2015/02/13 06:00 [entrez]
PHST- 2015/02/13 06:00 [pubmed]
PHST- 2015/10/29 06:00 [medline]
PHST- 2014/12/01 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2014 Dec 1;7(12):8609-15. eCollection 2014.